TW202345849A - 以iap拮抗劑化合物治療癌症之方法及組合療法 - Google Patents

以iap拮抗劑化合物治療癌症之方法及組合療法 Download PDF

Info

Publication number
TW202345849A
TW202345849A TW112107831A TW112107831A TW202345849A TW 202345849 A TW202345849 A TW 202345849A TW 112107831 A TW112107831 A TW 112107831A TW 112107831 A TW112107831 A TW 112107831A TW 202345849 A TW202345849 A TW 202345849A
Authority
TW
Taiwan
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
cancer
formula
Prior art date
Application number
TW112107831A
Other languages
English (en)
Chinese (zh)
Inventor
馬丁 約翰 席斯
智子 史密斯
喬治 艾伯特 瓦德
高譚 波塔克
Original Assignee
日商大塚製藥股份有限公司
美國德州系統大學評議委員會
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 日商大塚製藥股份有限公司, 美國德州系統大學評議委員會 filed Critical 日商大塚製藥股份有限公司
Publication of TW202345849A publication Critical patent/TW202345849A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TW112107831A 2022-03-04 2023-03-03 以iap拮抗劑化合物治療癌症之方法及組合療法 TW202345849A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263316680P 2022-03-04 2022-03-04
US63/316,680 2022-03-04

Publications (1)

Publication Number Publication Date
TW202345849A true TW202345849A (zh) 2023-12-01

Family

ID=85792184

Family Applications (1)

Application Number Title Priority Date Filing Date
TW112107831A TW202345849A (zh) 2022-03-04 2023-03-03 以iap拮抗劑化合物治療癌症之方法及組合療法

Country Status (7)

Country Link
US (1) US20250186451A1 (enExample)
EP (1) EP4486352A1 (enExample)
JP (1) JP2025508016A (enExample)
KR (1) KR20240156407A (enExample)
AU (1) AU2023229084A1 (enExample)
TW (1) TW202345849A (enExample)
WO (1) WO2023168394A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR122022015241B1 (pt) 2013-12-20 2023-09-26 Astex Therapeutics Limited Compostos heterocíclicos bicíclicos intermediários para a preparação de um composto de fórmula (i)
CN120379671A (zh) * 2022-10-18 2025-07-25 辉瑞公司 用于治疗癌症的化合物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
BR122022015241B1 (pt) 2013-12-20 2023-09-26 Astex Therapeutics Limited Compostos heterocíclicos bicíclicos intermediários para a preparação de um composto de fórmula (i)
GB201919219D0 (en) * 2019-12-23 2020-02-05 Otsuka Pharma Co Ltd Cancer biomarkers

Also Published As

Publication number Publication date
KR20240156407A (ko) 2024-10-29
US20250186451A1 (en) 2025-06-12
AU2023229084A1 (en) 2024-10-17
JP2025508016A (ja) 2025-03-21
EP4486352A1 (en) 2025-01-08
WO2023168394A1 (en) 2023-09-07

Similar Documents

Publication Publication Date Title
AU2022203810B2 (en) Methods of treating and preventing alloantibody driven chronic graft versus host disease
CN106413716B (zh) 通过jak和pi3k抑制剂组合治疗b细胞恶性肿瘤
US10047078B2 (en) Aminothiazole compounds
CN115607552B (zh) 取代的4-氨基异二氢吲哚-1,3-二酮化合物和第二种活性剂的组合用途
TW202529768A (zh) 癌症治療的療法
WO2023049831A1 (en) Treatment of human papillomavirus-associated cancers by pd-l1 inhibitors
TW201636348A (zh) 四氫－吡啶并［３，４－ｂ］吲哚雌激素受體調節劑及其用途
TW202345849A (zh) 以iap拮抗劑化合物治療癌症之方法及組合療法
TW202132299A (zh) 組合
BR112020022148A2 (pt) Métodos de tratamento de câncer
EP4436578A1 (en) Combination therapy comprising an fgfr inhibitor and a kras inhibitor
EP3790541B1 (en) N-(3-(azepan-1-ylsulfonyi)-phenyl)-2-((2-((3-phenyl)amino)-2-oxoethyl)(methyl)amino)-acetamide derivatives and related compounds as ras oncoprotein inhibitors for the treatment of cancer
US20220162200A1 (en) Pkm2 modulators and methods for their use
WO2023149450A1 (ja) Ｍａｌｔ１阻害薬を有効成分として含むがん治療剤
TW202135814A (zh) 組合
WO2024227033A1 (en) Heterocyclic compounds as parp1 inhibitors
HK40095032A (zh) 一种药物组合物及其在治疗癌症中的用途
HK40095032B (zh) 一种药物组合物及其在治疗癌症中的用途